XS0432810116

Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth

The U.S. Food and Drug Administration (FDA) has not raised any concerns related to the efficacy or safety of inclisiran.

The Committee voted 12 to 1 that the data presented support the use of Entresto in treatment of patients with

In Phase III KESTREL study, Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in

Phase III study did not meet its primary endpoint of reducing the number of hospitalized COVID-19 patients who experienced severe

Interim analysis from the investigational ELARA study shows, 65% of patients with r/r follicular lymphoma evaluated for efficacy achieved a

Results of REACH3 trial also demonstrate significant improvements in failure-free survival (FFS) and patient-reported symptoms1 Chronic graft-versus-host disease (GvHD) is

Novartis showcases unique profile with therapeutic area breadth and depth, exposure to cutting edge platforms and diversification of revenues in

Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress

Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress